Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Methotrexate Does Not Cause Rheumatoid Interstitial Lung Disease
Key clinical point: There is no association between incident interstitial lung disease (ILD) and methotrexate treatment in patients with RA.
Major finding: Methotrexate exposure was not associated with incident RA-ILD (odds ratio, 0.85; P = .578).
Study details: Two prospective, multicenter early RA inception cohorts involving 2,701 patients.
Disclosures: The study had no specific outside funding. The reporting investigator reported having no conflicts of interest.
Citation:
Kiely P et al. Rheumatology. 2019;58(suppl 3), Abstract 009.